T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy - Ghilardi, Guido; Fraietta, Joseph A.; Gerson, James N.; Van Deerlin, Vivianna M.; Morrissette, Jennifer J. D.; Caponetti, Gabriel C.; Paruzzo, Luca; Harris, Jaryse C.; Chong, Elise A.; Susanibar Adaniya, Sandra P.; Svoboda, Jakub; Nasta, Sunita D.; et al. (Nature medicine, 2024)
Keywords: 631/67/1059/2325; 631/67/1990; 692/308/409; 706/648/697/129; Antigens, CD19; B-cell lymphoma; Biomedical and Life Sciences; Biomedicine; Brief Communication; Cancer Research; CD19 antigen; CD8 antigen; Cell therapy; Chimeric antigen receptors; Cytotoxicity; Hematologic Neoplasms; Hematology; Humans; Immunotherapy; Immunotherapy, Adoptive - adverse effects; Infectious Diseases; Insertional mutagenesis; Lung cancer; Lung Neoplasms; Lymph nodes; Lymphocytes; Lymphocytes T; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Malignancy; Metabolic Diseases; Molecular Medicine; Neurosciences; Patients; Phenotypes; Receptors, Antigen, T-Cell - genetics; Receptors, Chimeric Antigen - genetics; T-cell lymphoma; Thorax; Transgenes